Camurus AB has completed a directed issue of SEK 300 million
Camurus has completed a directed issue to Swedish and international institutional investors raising SEK 300 million through an accelerated book building process.
Camurus is a Swedish research-based biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction. Camurus' shares are listed on Nasdaq Stockholm.
Camurus was advised by Mannheimer Swartling in the transaction.